The Lancet publishes Lundbeck Vyepti study

The firm’s study of migraine treatment Vyepti has been published in the top-ranking medical journal, which is a stamp of approval for Lundbeck’s research quality, according to Head of R&D Johan Luthman.
Photo: Lundbeck / PR
Photo: Lundbeck / PR
by marketwire, translated by daniel pedersen

The Lancet, a top-ranking medical journal, has published results from pharmaceutical firm Lundbeck’s Deliver study of migraine drug Vyepeti, the firm announced in a press release on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading